Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor

Reuters

2025/08/28

Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor

China Medical System Holdings Limited has announced that its subsidiary, Dermavon Holdings Limited, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for povorcitinib. This innovative oral small-molecule JAK1 inhibitor will be tested for the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa. Dermavon, an innovative pharmaceutical company specializing in skin health, is actively preparing to initiate these clinical trials and aims to launch the product as soon as possible. Dermavon is also pursuing an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, further amplifying its potential impact in the pharmaceutical industry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562403462"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562403462\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562403462?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562403462","market":"fut","top_or_hot":-1,"title":"Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Medical System Holdings Limited has announced that its subsidiary, Dermavon Holdings Limited, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for povorcitinib. This innovative oral small-molecule JAK1 inhibitor will be tested for the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa. Dermavon, an innovative pharmaceutical company specializing in skin health, is actively preparing to initiate these clinical trials and aims to launch the product as soon as possible. Dermavon is also pursuing an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, further amplifying its potential impact in the pharmaceutical industry.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CHSYF\">China Medical System Holdings Ltd</a>. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Medical System Holdings Limited has announced that its subsidiary, Dermavon Holdings Limited, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for povorcitinib. This innovative oral small-molecule JAK1 inhibitor will be tested for the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa. Dermavon, an innovative pharmaceutical company specializing in skin health, is actively preparing to initiate these clinical trials and aims to launch the product as soon as possible. Dermavon is also pursuing an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, further amplifying its potential impact in the pharmaceutical industry.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CHSYF\">China Medical System Holdings Ltd</a>. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BYV24P56.USD","symbol_name":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL7wfxq5:1","article_id":"2562403462","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562403462","pubTimestamp":1756382954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Medical System Holdings Limited has announced that its subsidiary, Dermavon Holdings Limited, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for povorcitinib. This innovative oral small-molecule JAK1 inhibitor will be tested for the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa. Dermavon, an innovative pharmaceutical company specializing in skin health, is actively preparing to initiate these clinical trials and aims to launch the product as soon as possible. Dermavon is also pursuing an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, further amplifying its potential impact in the pharmaceutical industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","00867":"康哲药业","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1191":"制药","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","BK1593":"医美概念股","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC"},"translate_title":"康哲药业旗下Dermavon Holdings创新JAK1抑制剂临床试验获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":0.9},"content_text":"Dermavon Holdings, a Subsidiary of China Medical System, Gains Approval for Clinical Trials on Innovative JAK1 Inhibitor\n    \n\n        China Medical System Holdings Limited has announced that its subsidiary, Dermavon Holdings Limited, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for povorcitinib. This innovative oral small-molecule JAK1 inhibitor will be tested for the treatment of non-segmental vitiligo and moderate to severe hidradenitis suppurativa. Dermavon, an innovative pharmaceutical company specializing in skin health, is actively preparing to initiate these clinical trials and aims to launch the product as soon as possible. Dermavon is also pursuing an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, further amplifying its potential impact in the pharmaceutical industry.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}